Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA4 | P22748 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317165 | 0.91 | CA1 (0.51) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL6318482 | 0.90 | CA1 (0.50) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL6319066 | 0.89 | CA1 (0.53) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL885646 | 0.88 | CA1 (0.39) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL6317716 | 0.88 | CA1 (0.54) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL6321595 | 0.87 | CA1 (0.55) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL6321134 | 0.85 | CA1 (0.49) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL885511 | 0.85 | C3AR1 (0.41) | CA1CA2CA4CA7 | |
| SCHEMBL6316380 | 0.84 | CA1 (0.53) | CA1CA2CA4CA7PTGS1 | |
| SCHEMBL6322758 | 0.84 | CA1 (0.54) | CA1CA2CA4CA7PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197633-A1 | N-Alkyl-Heterocyclyl Carboxamide Derivatives | BAYER CROPSCIENCE S.A. (FR) | 2010-08-05 | — | — | US | claimed |
| EP-1937637-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-07-02 | — | — | EP | claimed |
| WO-2007039615-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-04-12 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| CN-1549714-A | Aminoisoxazole derivatives active as kinase inhibitors | — | 2004-11-24 | — | — | CN | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-8148538-B2 | N-alkyl-heterocyclyl carboxamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20100197633-A1 | N-Alkyl-Heterocyclyl Carboxamide Derivatives | BAYER CROPSCIENCE S.A. (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-1937637-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039615-A1 | NEW N-ALKYL-HETEROCYCLYL CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-04-12 | — | — | WO | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | CA1 2406/4885CA2 2764/4885CA4 4029/4885 |
| US-20100197633-A1 | N-Alkyl-Heterocyclyl Carboxamide Derivatives | CYP1A2, CYP3A7, GANC | CA1 1573/4885CA2 606/4885CA4 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.